Epizyme Inc (NASDAQ:EPZM) reported earnings of ($0.42) per share beating Walls Streets expectations.

Epizyme Inc (NASDAQ:EPZM) reported Q2 2018 earnings this Morning, coming in at ($0.42) per share, beating Wall Street’s estimates of ($0.53) per Share. Revenue for the quarter came in at $12.00 million beating analyst estimates of $0.54 million

Recent Insider Trading for Epizyme Inc (NASDAQ:EPZM)

  • On 2/5/2018 Matthew Ros, COO, sold 72,264 with an average share price of $16.63 per share and the total transaction amounting to $1,201,750.32.
  • On 10/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $16.44 per share and the total transaction amounting to $246,600.00.
  • On 9/25/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $16.81 per share and the total transaction amounting to $252,150.00.
  • On 9/18/2017 David M Mott, Director, bought 200,000 with an average share price of $15.25 per share and the total transaction amounting to $3,050,000.00.
  • On 8/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $15.68 per share and the total transaction amounting to $235,200.00.
  • On 7/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $13.44 per share and the total transaction amounting to $201,600.00.
    Story continues below



    About Company
    Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

    Recent Analyst Rating for Epizyme Inc (NASDAQ:EPZM)



      Recent Trading for Epizyme Inc (NASDAQ:EPZM)
      Shares of Epizyme Inc closed the previous trading session at 9.90 −3.10 23.85% with 8.61 shares trading hands.

      An ad to help with our costs